Skip to main content

Advertisement

Table 2 Percentage of cells expressing IHC detectable MMP3, -7 or -13 following incubation of tissue in standard medium, or medium supplemented with IL-1 or IL-1Ra for 48 hours

From: Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy study

    MMP3 MMP7 MMP13
    Mean (percent) SEM Mean (percent) SEM Mean (percent) SEM
Non-degenerate NP Untreated 0.9 1.0 4.2 2.1 2.7 0.9
   IL-1 6.5 1.2 35.8 7.6 11.3 5.2
   IL-1Ra 0 0.0 0.2 0.1 0.2 0.1
  AF Untreated 0.3 0.2 0.4 0.2 0.3 0.2
   IL-1 1.2 0.5 1.9 0.9 1.5 0.5
   IL-1Ra 0.0 0.0 0.2 0.1 0.0 0.0
Moderately degenerate NP Untreated 10.2 4.1 72.6 10.9 31.9 7.7
   IL-1 14.1 5.6 83.4 10.1 38.2 10.7
   IL-1Ra 0.0 0.0 3.3 1.2 2.7 1.1
  AF Untreated 1.9 0.9 3.5 1.1 1.0 0.4
   IL-1 2.8 1.4 5.1 0.9 1.5 0.5
   IL-1Ra 0.2 0.1 0.2 0.1 0.1 0.1
Severely degenerate NP Untreated 3.6 1.2 17.9 6.0 16.2 7.2
   IL-1 6.5 3.1 19.4 6.5 19.9 6.3
   IL-1Ra 0.2 0.1 2.2 1.1 2.1 1.2
  AF Untreated 2.0 0.4 0.9 0.4 0.2 0.1
   IL-1 2.8 0.7 1.1 0.2 2.3 0.7
   IL-1Ra 0.2 0.1 0.2 0.1 0.1 0.0
  1. AF, annulus fibrosus; IHC, immunohistochemistry; IL-1Ra, interleukin-1 receptor antagonist; MMP, matrix metalloproteinase; NP, nucleus pulposus; SEM, standard error of the mean.